Overview

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

Status:
Completed
Trial end date:
2020-01-23
Target enrollment:
Participant gender:
Summary
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
Phase:
Phase 2
Details
Lead Sponsor:
DiaMedica Therapeutics Inc
DiaMedica USA Inc.
Treatments:
Kallikreins